Yang Kun, Liu Wenxian, Ren Wei, Lv Shuzheng
Department of Coronary Care Unit (CCU), Capital Medical University Affiliated Beijing Anzhen Hospital, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, 100029, China.
Int Urol Nephrol. 2014 Sep;46(9):1801-7. doi: 10.1007/s11255-014-0765-3. Epub 2014 Jun 26.
This study aimed to observe the preventive potential of different hydration solutions on contrast-induced nephropathy (CIN) after percutaneous coronary intervention.
We initially screened 627 patients who were admitted to the Division of Cardiology, Beijing Anzhen Hospital between October 2010 and October 2011. The research subjects were randomly divided into four groups and were given: normal physiological saline (PS), sodium bicarbonate (SB), oral administration of PS + N-acetylcysteine (NAC) (PS + NAC), or oral administration of SB + NAC (SB + NAC). These patients were administered a hypotonic nonionic contrast agent, and the incidence of CIN in each group was observed.
The total incidence rate of CIN was 4.47 %, while the CIN incidence rates in the PS group, the SB group, the PS + NAC group and the SB + NAC group were 3.11, 5.03, 4.46 and 5.33 %, respectively. The differences between these groups were not statistically significant (P = 0.238), and for patients with diabetes and/or renal dysfunction, the incidence rates of CIN among the four groups did not show statistically significant differences (P = 0.238, 0.156, 0.287).
Use of PS, SB, and NAC caused no significant reduction in the incidence of CIN, but in high-risk patients with diabetes and/or renal dysfunction, SB + NAC might be superior to the application of isotonic crystalloid solution.
本研究旨在观察不同水化溶液对经皮冠状动脉介入术后对比剂肾病(CIN)的预防潜力。
我们最初筛选了2010年10月至2011年10月在北京安贞医院心内科住院的627例患者。研究对象被随机分为四组,并分别给予:生理盐水(PS)、碳酸氢钠(SB)、口服PS + N - 乙酰半胱氨酸(NAC)(PS + NAC)或口服SB + NAC(SB + NAC)。这些患者接受了低渗非离子型对比剂,并观察每组CIN的发生率。
CIN的总发生率为4.47%,而PS组、SB组、PS + NAC组和SB + NAC组的CIN发生率分别为3.11%、5.03%、4.46%和5.33%。这些组之间的差异无统计学意义(P = 0.238),对于糖尿病和/或肾功能不全患者,四组中CIN的发生率也无统计学差异(P = 0.238、0.156、0.287)。
使用PS、SB和NAC并未显著降低CIN的发生率,但在糖尿病和/或肾功能不全的高危患者中,SB + NAC可能优于等渗晶体溶液的应用。